About Drug-Eluting Stent
Drug-eluting stents, also known as medicated coronary stents, are used to inhibit artery blockages that may occur in patients after an angioplasty surgery. A drug-eluting stent is a tiny, expandable metal mesh tube, which is covered with a pharmacologic agent (drug). Drug-eluting stents are used to treat patients that suffer from atherosclerosis that can occur because of hypertension, smoking, a sedentary lifestyle, or a high-cholesterol diet. After a patient undergoes angioplasty, there is a chance that the artery might close again because of blood clots or excessive growth of the surrounding tissues. To address this problem, drug-eluting stents are placed in the artery, preventing it from narrowing or clogging. Thus, drug-eluting stents eliminate the need for repeated revascularization procedures that are used to treat restenosis (narrowing of blood vessels). Restenosis of an artery occurs because of the body’s natural immune response to an injury. Drug-eluting stents help in reducing the arterial blockage and ensure smooth blood flow through the arteries.
Technavio’s analysts forecast the global drug-eluting stent market to grow at a CAGR of 3.45% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global drug-eluting stent market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drug-eluting stent products.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Drug-Eluting Stent Market 2016-2020
Technavio recognizes the following companies as the key players in the Global Drug-Eluting Stent Market: Abbott Laboratories, Biosensors International Group, Boston Scientific, Medtronic, and Terumo Corporation.
Other Prominent Vendors in the market are: Biotronik, Cook Medical, Envision Scientific, Lepu Medical, Meril Life Sciences, MicroPort Medical, Opto Circuits, Shandong JW Medical Systems and STENTYS.
Commenting on the report, an analyst from Technavio’s team said: “The drug-eluting stent market is a matured market with the presence of many vendors. To survive in the competitive environment, maintaining the market share is important that will lead to an increase in mergers and acquisitions, sales agreements, and distribution agreements.”
According to the report, an increase in the incidence of atherosclerosis diseases such as angina, heart attack, stroke, and transient ischemic attack is the primary driver for the growth of the global drug-eluting stent market. A drug-eluting stent is used in the treatment of atherosclerosis diseases. Rise in obesity, excessive smoking, diabetes, alcohol consumption, and unhealthy lifestyle are the major factors that contribute to the increased incidence of atherosclerosis diseases.
Further, the report states that the declining average selling price of drug-eluting stents is however impeding market growth. The competition in the market has increased with the growing presence of many local vendors. This factor pushes vendors to adopt a competitive pricing strategy that results in the decline in the price of products, affecting the profit margins of global vendors.
Abbott Laboratories, Biosensors International Group, Boston Scientific, Medtronic, Terumo Corporation, Biotronik, Cook Medical, Envision Scientific, Lepu Medical, Meril Life Sciences, MicroPort Medical, Opto Circuits, Shandong JW Medical Systems, STENTYS.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook